Management of Mild Chronic Kidney Disease with Hypertension and Prediabetes

Introduction to Management

The American Journal of Kidney Diseases recommends comprehensive cardiorenal risk reduction with SGLT2 inhibitor initiation, ACE inhibitor or ARB for blood pressure control targeting <130/80 mmHg, lifestyle interventions including sodium restriction to <2g/day, and consideration of metformin or GLP-1 RA to prevent progression to diabetes 1, 2, 3

The American Journal of Kidney Diseases suggests target blood pressure should be <130/80 mmHg given the presence of prediabetes and CKD, which places this patient at high cardiovascular risk 4, 5
Initiate an ACE inhibitor or ARB as first-line therapy, titrated to the highest tolerated dose, as these agents provide both blood pressure control and cardiorenal protection, particularly important in patients with diabetes risk and CKD 6, 2, 3, 7
Monitor for hyperkalemia and acute kidney function changes after initiation 7
Add additional antihypertensive agents if blood pressure target is not achieved with monotherapy 4

The Kidney International guideline recommends target HbA1c should be maintained at <6.5% to prevent progression to type 2 diabetes, with aggressive intervention given the presence of CKD 6, 2, 8
Initiate an SGLT2 inhibitor immediately if eGFR ≥30 ml/min/1.73m², as these agents provide cardiorenal protection independent of glucose-lowering effects and reduce cardiovascular events 2, 3, 1
Consider metformin as additional therapy if eGFR ≥45 ml/min/1.73m², as metformin prevents progression from prediabetes to diabetes and is safe in mild CKD 2, 3, 9, 1
GLP-1 receptor agonist should be added if ≥7% weight reduction is not achieved with lifestyle alone and obesity is present, as these agents provide cardiovascular benefits, promote weight loss, and have low hypoglycemia risk 1, 3, 9

The American Journal of Kidney Diseases suggests sodium intake must be restricted to <2g/day, and consume a diet high in vegetables, fruits, whole grains, fiber, legumes, plant-based proteins, unsaturated fats, and nuts 7, 2, 5, 3
Limit processed meats, refined carbohydrates, and sweetened beverages 2, 3, 8
Maintain protein intake at 0.8 g/kg/day, and avoid high protein intake >1.3 g/kg/day as it may accelerate CKD progression 7, 2, 3
Undertake moderate-intensity physical activity for at least 150 minutes per week, as exercise should be compatible with cardiovascular health and tolerance 7, 2, 5, 3
Achieve and maintain a healthy weight (BMI 20-25 kg/m²), and complete smoking cessation is mandatory, as smoking increases CKD progression risk and cardiovascular events 7, 5, 6, 2

The Metabolism: Clinical and Experimental guideline recommends initiate statin therapy immediately, as this patient is at high cardiovascular risk due to CKD and prediabetes 1, 4
Target LDL-C <70 mg/dl with at least 50% reduction from baseline for stage 3 CKD, and statins are first-line therapy, with ezetimibe added if LDL-C target not achieved 4, 1

Monitor HbA1c every 3-6 months to track glycemic control, and check eGFR and albuminuria at least annually, more frequently if eGFR <60 ml/min/1.73m² 6, 2, 8, 9
Monitor serum potassium after initiating ACE inhibitor/ARB, particularly if adding SGLT2 inhibitor, and assess for volume depletion when starting SGLT2 inhibitor 7, 2, 10
Screen for cardiovascular complications given elevated risk 9

Do not delay SGLT2 inhibitor initiation, as these agents should be started immediately in CKD with prediabetes for cardiorenal protection, not reserved only for diabetes 1, 2
Do not use combination ACE inhibitor plus ARB, as this increases harm without additional benefit 7
Do not target HbA1c <6.5% if hypoglycemia risk is present, but this patient with prediabetes has minimal hypoglycemia risk 7, 6, 8
Do not overlook albuminuria testing, as presence of albuminuria would intensify treatment targets and confirm need for ACE inhibitor/ARB 6, 2
Do not use first-generation sulfonylureas if additional glucose-lowering is needed, as they increase hypoglycemia risk in CKD 9